The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.

Immunome’s acquired gamma secretase inhibitor, varegacestat, has demonstrated its efficacy and tolerability in a Phase III study, meaning the company will now file for the drug’s approval with the FDA ...

Rezolute still has another Phase III trial of ersodetug in progress to rely upon, with data expected in H2 2026.

Speaking at CDMI Europe 2025, GlobalData pharma analyst George El-Helou says the use of AI in R&D could help mitigate patent ...

Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...

The solution leverages AI to match molecular, demographic, and clinical history data against eligibility criteria from active trials. Credit: MUNGKHOOD STUDIO / Shutterstock.com. Anova Enterprises has ...

Recently, artificial intelligence (AI) has been paving the way and helping sponsors with patient identification and participant retention. Digital twins, a new technological frontier in the AI space, ...

The pipeline continues to look strong for HIV but the hunt for a cure or vaccine continues. Image credit: Shutterstock / PENpics Studio The year 2023 started with disappointing news for the field of ...

There have been several impactful clinical trial read outs in 2024. Image credit: Shutterstock / Rajitha Tennakoon From gene therapies to psychedelics and cancer vaccines to HIV pre-exposure ...

The clinical trial sector reflects on what it believes will be the biggest difficulties of 2025. Image credit: Shutterstock / 3rdtimeluckystudio It has been a turbulent time for the pharmaceutical ...

AI technology in clinical trials has the potential to speed up cohort selection and patient recruitment. However, data management and inherit bias in datasets need to be addressed first.